Medulloblastoma overview

Jump to navigation Jump to search

Medulloblastoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Medulloblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Medulloblastoma overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Medulloblastoma overview

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Medulloblastoma overview

CDC on Medulloblastoma overview

Medulloblastoma overview in the news

Blogs on Medulloblastoma overview

Directions to Hospitals Treating Medulloblastoma

Risk calculators and risk factors for Medulloblastoma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

Medulloblastoma is a malignant primary brain tumor that originates in either the cerebellum or the posterior cranial fossa. The term medulloblastoma was first used to describe the tumor by Dr. Harvey Cushing, an American neurosurgeon, in 1924.[1] Medulloblastoma may be classified into several subtypes based on the WHO histological classification system(classic vs variant medulloblastoma) and the molecular subtypes classification system(WNT subgroup vs SHH subgroup vs Group 3 medulloblastoma vs Group 4 medulloblastoma).[2][3][4][5][6] Medulloblastoma arises from the cerebellar stem cells, which are normally involved in the anatomical development of the cerebellum and other posterior fossa structures. Medulloblastoma is an invasive and rapidly growing brain tumor which frequently metastasize to different organs of the body. Genes involved in the pathogenesis of medulloblastoma include CTNNB1 gene, PTCH1 gene, and MLL2 gene. On gross pathology, a pink, solid, and well circumscribed mass is a characteristic finding of medulloblastoma. On microscopic histopathological analysis, round tumor cells, elevated mitotic rate, increased nucleus:cytoplasmic ratio, and Homer-Wright rosettes are characteristic findings of medulloblastoma.[5] Medulloblastoma must be differentiated from other diseases that cause morning headache, recurrent vomiting, nausea, restlessness, and poor feeding among children such as ependymoblastoma, cerebral neuroblastoma, and pineal tumor.[7] Common complications of medulloblastoma include hydrocephalus, decerebrate attacks, and cranial nerve palsies. Medulloblastoma is the second most common brain tumor among the pediatric population.[8] Prognosis is generally good, the 5-year survival rate of patients with medulloblastoma is approximately 69%.[8] The staging of medulloblastoma is based on the modified Chang's staging system. Medulloblastoma patients are risk stratified into either standard risk group or high risk group based on the tumor stage, patient's age, and the extent of any previous surgical resection.[9][10] The hallmark of medulloblastoma is morning headache. Other common symptoms of medulloblastoma include recurrent vomiting, restlessness, and frequent falls.[8] Brain MRI with gadolinium based contrast is the investigation of choice for the diagnosis of medulloblastoma. On a T1 weighted brain MRI image, medulloblastoma is characterized by a hypointense mass located at the posterior cerebral fossa that may demonstrate calcification and necrosis. [6] According to the risk stratification criteria for medulloblastoma patients, surgery must be followed by the appropriate radiotherapy or chemotherapy management.[11]

Historical Perspective

The term medulloblastoma was first used to describe the tumor by Dr. Harvey Cushing, an American neurosurgeon, in 1924.[1]

Classification

Medulloblastoma may be classified into several subtypes based on the WHO histological classification criterion (classic vs variant medulloblastoma) and the molecular subtypes classification criterion (WNT subgroup vs SHH subgroup vs Group 3 medulloblastoma vs Group 4 medulloblastoma).[2][3][4][5][6]

Pathophysiology

Medulloblastoma arises from the cerebellar stem cells, which are normally involved in the anatomical development of the cerebellum and other posterior fossa structures. Medulloblastoma is an invasive and rapidly growing brain tumor which frequently metastasize to different organs of the body. Genes involved in the pathogenesis of medulloblastoma include CTNNB1 gene, PTCH1 gene, MLL2 gene, SMARCA4 gene, DDX3X gene, CTDNEP1 gene, KDM6A gene, and TBR1 gene. Medullobastomas is associated with a number of syndromes that include Gorlin syndrome and Turcot syndrome.[8] On gross pathology, a pink, solid, and well circumscribed mass is a characteristic finding of medulloblastoma. On microscopic histopathological analysis, round tumor cells, elevated mitotic rate, increased nucleus:cytoplasmic ratio, and Homer-Wright rosettes are characteristic findings of medulloblastoma.[5]

Causes

There are no established direct causes for medulloblastoma. The development of medulloblastoma is the result of multiple genetic mutations.[8]

Differentiating Medulloblastoma from other Diseases

Medulloblastoma must be differentiated from other diseases that cause morning headache, recurrent vomiting, nausea, restlessness, and poor feeding among children such as ependymoblastoma, cerebral neuroblastoma, and pineal tumor.[7]

Epidemiology and Demographics

Medulloblastoma is the second most common brain tumor among the pediatric population.[8] The overall age adjusted incidence rate of medulloblastoma is approximately 0.71 per 100,000 individuals in the United States.[12] The incidence of medulloblastoma decreases with age; the median age at diagnosis is between 5 to 7 years.[11] Males are more commonly affected with medulloblastoma than females. The male to female ratio is approximately 1.44 to 1.[12]

Risk Factors

There are no established risk factors for medulloblastoma.

Screening

According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for medulloblastoma.[13]

Natural History, Complications and Prognosis

If left untreated, patients with medulloblastoma may progress to develop ataxia, nystagmus, and positional dizziness. Common complications of medulloblastoma include hydrocephalus, decerebrate attacks, and cranial nerve palsies. Prognosis is generally good, the 5-year survival rate of patients with medulloblastoma is approximately 69%.[8] Physical examination of patients with medulloblastoma is usually remarkable for strabismus, nystagmus, motor weakness, and ataxia.[8][11]

Diagnosis

Staging

The staging of medulloblastoma is based on the modified Chang's staging system. Medulloblastoma patients are risk stratified into either standard risk group or high risk group based on the tumor stage, patient's age, and the extent of any previous surgical resection.[9][10]

History and Symptoms

The hallmark of medulloblastoma is morning headache. Other common symptoms of medulloblastoma include recurrent vomiting, restlessness, and frequent falls.[8]

Physical Examination

Patients with medulloblastoma usually appear restless. Physical examination of patients with medulloblastoma is usually remarkable for strabismus, nystagmus, motor weakness, and ataxia.[8][11]

Laboratory Findings

There are no diagnostic lab findings associated with medulloblastoma.

CT

On head CT scan, medulloblastoma is characterized by a hyperdense mass arising from the cerebellar vermis, effacement of the fourth ventricle, and dilated ventricles due to obstructive hydrocephalus.[6]

MRI

Brain MRI with gadolinium based contrast is the investigation of choice for the diagnosis of medulloblastoma. On a T1 weighted brain MRI image, medulloblastoma is characterized by a hypointense mass located at the posterior cerebral fossa that may demonstrate calcification and necrosis.[6]

Other Imaging Findings

Magnetic resonance spectroscopy (MR spectroscopy) study for medulloblastoma demonstrates an elevated choline level and a reduced N-acetyl aspartate level. MR spectroscopy study also demonstrates a peak in taurine level.[6]

Other Diagnostic Studies

Bromodeoxyuridine labeling study may be helpful in the diagnosis of medullblastoma. An elevated bromodeoxyuridine labeling index is suggestive of a rapid growth rate of medulloblastoma.[14]

Treatment

Medical Therapy

Risk stratification determines the protocol of management used for medulloblastoma patients. Radiotherapy is the mainstay of treatment for medulloblastoma. Radiotherapy for medulloblastoma must be started within the 6 weeks period following surgery. Adjunctive chemotherapy is also required for the management of certain medulloblastoma patients. Recommended chemotherapeutic regimens used for the management of standard risk medulloblastoma patients include a combination of lomustine AND vincristine AND cisplatin.[15][16]

Surgery

Surgical intervention alone is not recommended as a single therapeutic modality for the management of medulloblastoma. According to the risk stratification criteria for medulloblastoma patients, surgery must be followed by the appropriate radiotherapy or chemotherapy management. Surgical excision of medulloblastoma may be done either via a posterior fossa craniectomy approach or a suboccipital craniectomy approach. Complications related to surgery may include aseptic meningitis, haematoma formation, and posterior fossa syndrome.[11]

References

  1. 1.0 1.1 Kunschner LJ (2002). "Harvey Cushing and medulloblastoma". Arch Neurol. 59 (4): 642–5. PMID 11939903.
  2. 2.0 2.1 Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T; et al. (2012). "Subgroup-specific structural variation across 1,000 medulloblastoma genomes". Nature. 488 (7409): 49–56. doi:10.1038/nature11327. PMC 3683624. PMID 22832581.
  3. 3.0 3.1 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A; et al. (2007). "The 2007 WHO classification of tumours of the central nervous system". Acta Neuropathol. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC 1929165. PMID 17618441.
  4. 4.0 4.1 Leary SE, Olson JM (2012) The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr 24 (1):33-9. DOI:10.1097/MOP.0b013e32834ec106 PMID: 22189395
  5. 5.0 5.1 5.2 5.3 Medulloblastoma. Libre Pathology(2015) http://librepathology.org/wiki/index.php/Medulloblastoma Accessed on September, 28 2015
  6. 6.0 6.1 6.2 6.3 6.4 6.5 Medulloblastoma. Radiopaedia(2015) http://radiopaedia.org/articles/medulloblastoma Accessed on September, 28 2015
  7. 7.0 7.1 Types of childhood brain and spinal cord tumours> Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal-childhood/childhood-brain-and-spinal-tumours/types-of-tumours/?region=mb Accessed on September, 28 2015
  8. 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 Medulloblastoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Medulloblastoma Accessed on September, 28th 2015
  9. 9.0 9.1 Harisiadis L, Chang CH (1977). "Medulloblastoma in children: a correlation between staging and results of treatment". Int J Radiat Oncol Biol Phys. 2 (9–10): 833–41. PMID 597384.
  10. 10.0 10.1 Medulloblastoma staging. Wikibooks(2015) https://en.wikibooks.org/wiki/Radiation_Oncology/Medulloblastoma/Staging Accessed on September, 282015)
  11. 11.0 11.1 11.2 11.3 11.4 Bartlett F, Kortmann R, Saran F (2013). "Medulloblastoma". Clin Oncol (R Coll Radiol). 25 (1): 36–45. doi:10.1016/j.clon.2012.09.008. PMID 23245832.
  12. 12.0 12.1 McKean-Cowdin R, Razavi P, Barrington-Trimis J, Baldwin RT, Asgharzadeh S, Cockburn M; et al. (2013). "Trends in childhood brain tumor incidence, 1973-2009". J Neurooncol. 115 (2): 153–60. doi:10.1007/s11060-013-1212-5. PMC 4056769. PMID 23925828.
  13. Recommendations. US preventive services task force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=medulloblastoma Accessed on September, 28th 2015
  14. Onda K, Davis RL, Edwards MS (1996). "Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods". J Neurooncol. 29 (2): 129–36. PMID 8858517.
  15. von Hoff K, Rutkowski S (2012). "Medulloblastoma". Curr Treat Options Neurol. 14 (4): 416–26. doi:10.1007/s11940-012-0183-8. PMID 22622599.
  16. Clinical Practice Guidelines in Oncology Central Nervous System Cancers. National Comprehensive Cancer Network.(2015) http://www.lecba-rakoviny.cz/dokumenty/NCCN_Guidelines_cns_2011.pdf Accessed on September,25 2015


Template:WikiDoc Sources